Humanigen — KaloBios Pharmaceuticals — Investor Presentation (December 2015)
27 slides from Humanigen's investor presentation, Dec 4, 2015
Slide 1: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements include, but are not limited to, statements about: our ability to raise adequate capital to fund our product development programs and continued operations
Slide 2: Overview
Overview The Shkreli Group has acquired a controlling stake of KaloBios Martin Shkreli named Chairman and CEO of KaloBios New shareholder-oriented Board of Directors Permanent access to capital and M&A deal flow Turnaround focused on benznidazole and lenzilumab Benznidazole is the standard of care f
Slide 3: Turnaround Strategic Focus
Lenzilumab Strategic Focus Turnaround Corporate Overview Rare disease therapeutics clinical development Business development expertise Focused on lenzilumab (formerly KB003) Initiating Phase 1/2 study in CMML by YE 2015 Initiate Phase 2 study in JMML in 1H 2016 Initiate multiple proof-of-concept stu
Slide 4: Corporate Overview
Corporate Overview @ NASDAO-listed company headquartered in San Franci NASDAQ | KBIO. @ $7 million in cash and investments at end of Q3 2015 @ Nodebt @ Rare disease therapeutics clinical development @ Business development expertise @ Known standard of care with rapid approval possible @ Strong comme
Slide 5: Transaction Overview
Transaction Overview KaloBios has entered into an agreement with Savant Neglected Diseases, LLC (“Savant”) to acquire the worldwide rights to Savant’s benznidazole program, a compound being developed for the treatment of Chagas Disease Savant will receive: Upfront payment of $2M Regulatory milestone
Slide 6: Chagas Disease
Chagas Disease Chagas Disease is a chronic parasitic infection caused by Trypanosoma cruzi Chagas Disease affects approximately 8mm people in Latin America and >300,000 in the United States (CDC) Third most common parasitic disease globally Acute infection presents with mild, non-specific symptoms s
Slide 7: Substantial Disease Burden in the US & EU
Substantial Disease Burden in the US & EU Most common form of non-ischemic cardiomyopathy in Latin America 5-7 million infected, 1.4-2.1 million develop cardiomyopathy within 20-30 years 30,000 - 45,000 Chagas-related cardiomyopathy cases in the US (Bern and Montgomery, 2009) 63-315 congenital infec
Slide 8: Transmission and Acute Clinical Presentation
Transmission and Acute Clinical Presentation Lancet 2010; 375: 1388–402 Chagas is transmitted to humans by contact with feces of triatomine insects, sometimes called “kissing bugs” Triatomine bugs often bite the face humans, defecating shortly thereafter Patients can become infected if the bug feces
Slide 9: Chronic Disease
Chronic Disease Following the acute phase, untreated patients will remain infected for the rest of their lives More than 30% will develop severe cardiac or intestinal complications over the course of 10-30 years Cardiac complications include cardiomyopathy, heart failure, thromboembolism and cardiac
Slide 10: Years of data supporting its use as the preferred agent for Chagas
Over 40 years of data supporting its use as the preferred agent for Chagas Reductive metabolites of benznidazole create highly reactive oxygen species in T.cruzi, leading to DNA damage and thiol depletion 60 day course of treatment leads to long-term parasitological cure in majority (>60%) of acute
Slide 11: Regulatory & Exclusivity
Regulatory & Exclusivity FDA minutes reflect our expectation that no Chagas clinical trials will be required PK, CMC and toxicology studies will enable a NDA filing in 2016 Savant and its predecessor have made significant progress on NDA-enabling requirements NCE status allows for 5 years of exclusi
Slide 12: Benznidazole Timeline
Benznidazole Timeline Q415 Q116 Q216 Q316 Q416 Q117 CMC PK Study Non-Clinical Studies NDA Filing 13
Slide 13: Priority Review Voucher
Priority Review Voucher KaloBios may be eligible to receive a Priority Review Voucher (“PRV”) upon approval A PRV is transferable and saleable to another pharmaceutical company and confers a priority review to any New Drug Application Recent PRV sales have generated as much as $350 million in procee
Slide 14: Commercial Opportunity
Commercial Opportunity Pricing expected to be similar to Hepatitis C antivirals We expect 3,000 - 7,000 patients will require acute Chagas infection treatment with benznidazole annually Patient population upside is difficult to predict 30,000 – 45,000 chronic Chagas cardiomyopathy 100x upside exists
Slide 15: Commercial Opportunity
Commercial Opportunity © Pricing expected to be similar to Hepatitis C antivirals © We expect 3,000 - 7,000 patients will require acute Chagas infection treatment with benznidazole annually ¢ Patient population upside is difficult to predict ¢ 30,000 - 45,000 chronic Chagas cardiomyopathy ¢ 100x ups
Slide 16: Lenzilumab
Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) monoclonal antibody IgG1, 31pM affinity Prior clinical experience in asthma and rheumatoid arthritis showed biological activity and a good safety profile Potential in monocytosis leukemias such as CMML and JMML Potential in a variety of autoi
Slide 17: GM-CSF Biology
GM-CSF Biology 144-Amino Acid Cytokine GM-CSF Receptor is expressed on myeloblasts and other progenitor cells Binding results in differentiation and maturation into monocytes Binding of GM-CSF to its receptor results in phosphorylation of STAT5 pSTAT5-flow assay can determine sensitivity of differen
Slide 18: CMML (Chronic Myelomonocytic Leukemia)
CMML (Chronic Myelomonocytic Leukemia) Monocytosis is the cardinal feature of CMML >1g/L monocyte count in peripheral blood for > 3 months No defining cytogenetic abnormality; heterogeneous illness TET2, ASXL mutation in 35-50% of cases 3-year survival is 20% Median Overall Survival of 20 months 15-
Slide 19: GM-CSF in CMML
GM-CSF in CMML GM-CSF drives monocytosis in CMML Ramshaw et al. (2002) demonstrate early, low-affinity GM-CSFR antagonist E21R inhibits CMML colony formation in vitro 20
Slide 20: GM-CSF in CMML – Human case report
GM-CSF in CMML GM-CSF drives monocytosis in CMML – Human case report Bernard et al. (2002) publish first-in-human case report of E21R in a JMML patient in Blood 21
Slide 21: GM-CSF in CMML
GM-CSF in CMML Recent work by Dr. Eric Padron, the PI of the lenzilumab CMML trial 22 Bone Marrow cells respond to low levels of GM-CSF (0.1 ng/ml) compared with IL-3 (10 ng/ml)
Slide 22: KB003 CMML Clinical Program
KB003 CMML Clinical Program 400 mg Dose Escalation Patients + 13 Additional Patients 600 mg ACCELERATED DOSE ESCALATION One patient enrolled at each dose level 3+3 design if safety issues noted Primary Objective: Safety & Dose SINGLE AGENT COHORT EXPANSION Previously Treated CMML Patients Dosing: Mo
Slide 23: Competition and Other Indications
Competition and Other Indications MOR103/GSK3196165 licensed by GSK for $29 million Development in Rheumatoid Arthritis, Multiple Sclerosis Rheumatoid Arthritis trial showed significant benefit vs. placebo (Behrens et al., 2014) Phase IIB currently recruiting JMML may be even more sensitive to GM-CS
Slide 24: Business Development
Business Development KaloBios is in near-term negotiations to acquire several assets in the next 30 to 90 days Addition of experienced business development team led by Patrick Crutcher Opportunities include transactions with large pharma, biotech and specialty pharma companies Reviewing both commerc
Slide 25: Corporate Milestones – FY 2015 - 2016
Corporate Milestones – FY 2015 - 2016 December 2015 KB003 CMML Phase 1 Study first patient dosed File 10-Q with new audit firm Close Savant transaction 1H 2016 KB003 CMML open-label Phase 1 data YE 2016 File benznidazole NDA FY 2015-2016 26
Slide 26: KaloBios Pharmaceuticals December 2015
KaloBios Pharmaceuticals NASDAQ: KBIO December 2015
Slide 27: (@KatoBios
af - ~ 4 ~ \j — V 2 2 (@KatoBios
KaloBios Pharmaceuticals — Investor Presentation (December 2015) on 6ix